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Abstract
Nuclear medicine techniques have a great deal of advantage of using gamma
radiation emitter radiolabeled compounds to diagnose the long list of infectious and
malignant disorders in human systems. The gamma emitter radionuclide-labeled
compounds are associated with single photon emission computed tomography
(SPECT) camera. SPECT camera mainly offers the detection and analysis of gamma
rays origin to furnish the imaging of defective organs in the body. There are about
85% radiopharmaceuticals in clinical practice which are being detected by SPECT
camera. The following chapter is an update about the SPECT radiopharmaceuticals
that were developed and tried for infection and cancer diagnosis.
Keywords: 99mTc-antibiotics, SPECT imaging, radiopharmaceuticals,
nuclear medicines, infection imaging
1. Introduction
Nuclear medicine technique (NMT) is a detection process that helps in obtaining
diagnostic results at molecular level of a disease. The technique is carried out by
administrating target-specific radioisotope-labeled organic/biomolecule to patient
and collecting the gamma signals through scintillating camera to diagnose the
infected organ/tissues. In contrast to advanced instrumental procedures such as
magnetic resonance imaging (MRI) and computed tomography (CT) scan, NMT
offers a wide range of detection limit. For example, NMT starts working from
molecular level when no morphological changes appear; however MRI and CT do
this job at the appearance of morphological changes in diseased tissues.
NMT works by administration of radiolabeled molecules (commonly known as
radiopharmaceuticals) to patients and acquisition of radiation collected through
scintillation camera. There are two main components of radiopharmaceuticals: the
organic/biomolecule and the radioisotope. The former approaches diseased cells/
tissues and accumulate there at diseased cells and the latter part emits radiation to
indicate the position of diseased area.
Diagnosis through NMT means the image of internal body organs like heart,
kidney, lungs, breast, brain, bones, tissues, or whole body using γ-emitting radio-
pharmaceuticals; for example, indium-111 (111In) and technetium-99m (99mTc)
labeled molecules. These radionuclides are labeled with a variety of compounds
including drugs, organic species, peptides, proteins, and antibodies and then
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injected into the patient’s body. Intravenously administrated radiopharmaceuticals
accumulate in specific body part or organ for which it is prepared and scans are
obtained by single photon emission computed tomography (SPECT) camera [1].
Scan generated by SPECT camera gives very fruitful information regarding disease
and tumor, which makes it easier for doctors to make decision about treatment
strategies.
A large number of compounds have been labeled with γ-emitting radiotracers
for imaging of different types of cancer and infection. Some of them are shown in
Table 1 below [2].
2. Radiopharmaceuticals
In radiopharmaceuticals, there is a radioactive component which is used for the
diagnosis and treatment of different malignancies. Only 5% of radiopharmaceuti-
cals are used for therapeutic purposes while the remaining has diagnostic applica-
tions. Radiopharmaceutical has two components: first one is pharmaceutical part
and the second is radiotracer as shown in Figure 1.
Targeted agent with labeled
radiotracer
Emitting
radiation
Cancer type/disease
Bombesine indium-111 γ-emitting Endocrine organ tumor
Pentadecapeptide Technetium-99m γ-emitting Breast and prostate cancer, gastro-entero-
pancreatic tumors and lung cancer
Oxdronate-99mTc γ-emitting Bones disease
Tilmanocept technetium-99m γ-emitting Breast cancer, melanoma and oral Cavity
cancer
Pertechnetate technetium-99m γ-emitting Urinary and bladder thyroid cancer
Iodinated bombesin I-125 γ-emitting Endocrine cancer cell growth in endocrine
organ breast, prostate, ovaries and testes
Bombesine rhenium-188 γ-emitting Prostate tumor
FDG-F-18 γ-emitting Soft tissue cancer and prostate cancer
Oxdronate-99mTc γ-emitting Bones disease
Table 1.
Gamma-emitting radiotracer for diagnostic imaging of different types of cancer and infection [1].
Figure 1.
Radiopharmaceutical and its design.
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Effectiveness of the radiopharmaceutical depends upon both parts. In order to
prepare a good and efficient radiopharmaceutical, the first step involves the selec-
tion of a pharmaceutical component which is very critical [3]. Pharmaceuticals that
have a preferable accumulation in targeted body organ, tissues, or cells should be
selected. After the selection of pharmaceutical component, pharmaceutical is
labeled with a suitable radiotracer. The radiopharmaceutical is subjected to admin-
istration after a routine quality control procedure. There are many disease targeted
radiolabeled agents or compounds that are commonly used for diagnosis and ther-
apeutic purpose. From diagnostic point of view, disease-targeted agents (either a
drug or any other compound) are labeled with γ-emitting radiotracer, and for
therapeutic purpose, these agents are labeled with β and α radiotracer like lutetium-
177 (177Lu) and Yatrium-90 (90Y) [4]. In Table 2, some of the disease-targeted
agents (radiopharmaceuticals) are shown which are used for diagnostic imaging
and therapeutic purpose of different diseases and cancers.
3. SPECT—radiopharmaceuticals
Radiopharmaceuticals which are used to diagnose the cancer and infection by
using the γ-emitting radionuclides such as 111In and 99mTc are known as SPECT
radiopharmaceuticals. The radiotracer which is used for diagnostic purposes should
have following properties [5]:
• Easy availability at nuclear medicine center
• Low cost
• Short effective half-life then labeled pharmaceutical
• Carrier free
• Nontoxic
Targeted agent with labeled radiotracer Emitting radiation Cancer type/disease
Metastron (89SrCl2) β-emitting Skeletal cancer
Radium-223 dichloride α-emitting Bone metastasis, breast and
prostate cancer
Samarium-153-EDTMP β-emitting Bone and prostate cancer
Table 2.
Commonly used radiopharmaceuticals for therapeutic purpose [4].
γ-emitting radiotracer Half-life (hours) Generator Gamma energy Abundance of
γ-emission (%age)
Indium-111 67.32 Cyclotron 0.l7l MeV
0.245 MeV
90.5
94
Technetium-99m 6.02 99mMo/99mTc 140 keV 88.9
Iodine-123 13.22 Cyclotron 159 keV 82.8
Table 3.
Common properties of γ-emitting radionuclides.
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• Free from α and β particles emission (with little emission)
• Biological half-life not greater than time of study
• Suitable energy range
• Chemically reactive to form coordinate covalent bonds with the compound
which is to be labeled
Common properties of γ-emitting radionuclides for SPECT imaging are given in
Table 3.
4. Characteristic of technetium-99m for labeling
More than 85% of radiopharmaceuticals which are being used to diagnose the
cancer and infection are 99mTc labeled. The reason for using the 99mTc is due to
following characteristics:
• Half-life of technetium is 6 hours which is sufficient to examine the catabolic
as well as anabolic processes which occur in patient and minimal radiation
exposure time to the patients [6].
• Energy of the γ-rays emitted by technetium is very low (140 keV) which does
not greatly damage the soft tissues of the patient body, although they have low
energy but can be detected by any sensitive gamma camera [7].
• Its excretion rate from the patient body is very fast.
• Its short half-life enables us to get the imaging information very quickly.
• Technetium is very reactive to make complex with compounds.
• Decay of technetium takes place through isomeric transitions due to which
electrons and gamma radiation of low energy is emitted. Therefore, beta
radiation exposure to patent is negligible.
• Due to the emission of same energy levels of gamma radiation, the detector
alignment becomes very accurate as no beta radiation is emitted.
• Most important property of technetium is that its oxidation state can be
changed according to the desired targeted body organ and parts, which makes
it possible to develop a biological technetium labeled compound which can
accumulate in high amount on that targeted organ and part of body which is
under investigation [8].
5. Chemistry of 99mTc and oxidation state for labeling
Technetium belongs to transition metal family; its electronic configuration and
physical properties are shown in table given below (Table 4). There are 22 isotopes
of the technetium, but none of them is stable in nature. Half-life of 99Tc is 0.25
million years in its ground state. Oxidation state of technetium varies from 3 to +7
4
Medical Isotopes
as shown in Table 4 below. This happens due to the 4d and 5s loss or gain of
electrons by 4d orbital. Different types of ligands which are used to label the
technetium and chemical conditions under which labeling process is accomplished
are responsible for steadiness of such types of oxidation state. It is observed that
technetium is found in nature in the form of halides (TcF6, TcCl6 and TcBr4, oxide,
[TcO2, Tc2O7], sulfides [Tc2S7], and pertechnetate
99mTcO4
 in +4 to +7 oxidation
states). Oxidation states of smaller values such as 1, +2, +3 are naturally stabilized
during complex formation with varieties of ligands; for example, +3 oxidation state
is stabilized by the chelating agent, methylene diphosphate [9]. Without the use of
these chelating agents in complex formation, the oxidation state will not remain
constant and technetium would oxidize to +4 oxidation state and eventually change
to +7 oxidation state which is most stable state in complex. The +5 and +6 oxidation
of technetium is habitually charged to +4 and +7 oxidation states as shown in the
following Eqs. 1 and 2 which is most stable regardless of their proportion.
3Tcþ5 2Tcþ4þ Tcþ7 (1)
3Tcþ6 Tcþ4 þ 2Tcþ7 (2)
The coordination number of the technetium during complex formation can be
changed between 4 and 9.
Properties of technetium Values
Atomic number 43
Atomic mass (amu) 98
Electronic configuration 1s2,2s2,2p6,3s2,3p6,3d10,4s2,4p6,4d6,5s1
Density gm/cm3 (at 25°C) 11.5
Oxidation state 3, 1, 0, +1,+2,+3,+4,+5,+6,+7 (+4 and +7
are more stable)
Melting point in Kelvin 2430.15
Boiling point in Kelvin 5150.15
Occurrence Solid state (naturally)
Electronagetivity 1.9
First, second, and third ionization energy (kJ/mol) 702, 1472, and 2850, respectively
Electron affinity (kJ/mol) 58
Heat of vaporization kJ/mol 660
Group VIIB (7)
Metal category Transitions metal
Period Fifth
Color Silvery gray
Numbers of isotopes Twenty-two
Table 4.
Physical and chemical properties of technetium.
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6. Reducing agents and reduction of 99mTcO4

Technetium generated by Moly generator presents in the form of sodium-
pertechnetate (99mTc-NaTcO4). In this pertechnetate ion, the oxidation state of
technetium is +7 and structure of the 99mTcO4
 is pyramid tetrahedron in which Tc
atom is present in the center of the tetrahedron with +7 oxidation state and four
oxygen atoms located at the apexes of the triangular pyramid. This geometry and
oxidation state is identical to the permanganate ion MnO4
 and perrhenate ion
ReO4
 ion. Structure of the pertechnetate ion TcO4
 is shown in Figure 2.
Pertechnetate 99mTcO4 is a nonreactive molecule and cannot be used directly for
labeling; therefore, it is necessary to reduce the pertechnetate from +7 oxidation
state to lower oxidation state for labeling purposes. For the reduction of the
pertechnetate 99mTcO4 form +7 oxidation state to lower oxidation state, a variety of
reducing agents are employed such as stannous citrate (C12H10O14Sn3), stannous
tartrate (C4H4O6Sn), stannous chloride (SnCl2.2H2O), concentrated hydrochloric
acid (HCl), dithionite (O4S2
2), ferrous sulfate (FeSO4), and sodium boro
tetrahdride (NaBH4). However, the most frequently used reducing agent in labeling
of the compounds with technetium process is stannous chloride dihydrate
(SnCl2.2H2O) [10]. Electrolysis can also be utilized as a method for reducing
sodium-pertechnetate (99mTc-NaTcO4) and use zirconium as an anode and labeling
compound. However, following common characteristics are being considered to
choose a reducing agent in 99mTc chemistry.
• It should give effectual reduction at compassionate pH environment.
• It should have long shelf life mean remain unaffected when they are stored for
long time.
• It should not incorporate within the final product of the complex.
• It should give well-defined oxidation state in order to generate intrinsic complex.
• It should not interfere with complex formation procedure.
Reduction of pertechnetate 99mTcO4 with the help of stannous chloride is
accomplished in acidic medium, and reaction is given below.
3Snþ2 3Snþ4 þ 6 e (3)
Figure 2.
Structure of pertechnetate ion 99mTcO4
.
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299mTcO4 þ 16H
þ
þ 6e99mTcþ4 þ 8H2O (4)
Overall reaction
299mTcO4 þ 16H
þ
þ 3Snþ2 99mTcþ4 þ 8H2Oþ 3Sn
þ4 (5)
It is clear from the Eq. 4 that technetium reduces from higher oxidation state +7
to lower oxidation state +4. Under different chemical and physical conditions, other
oxidation state of 99mTc such as 99mTc+3 and 99mTc+5 are likely to be formed or a
mixture of all these oxidation states could possibly exist. Stannous chloride as a
reducing agent is usually used in a very small amount while 99mTc is commonly
administrated in the concentration  109 M.
7. Labeling of chelating agents with reduce technetium
Technetium-99m after reduction forms reactive species and attains the ability to
bind with a variety of chelating agents to generate the labeled product. In order to
form the additive bond, normally, chelating agent donates the lone pairs of the
electrons to make coordinate covalent bond with 99mTc. Compounds containing the
electron donating group such as carboxylic group (dCOOH), amines (dNH2),
hydroxyl (dOH), and thiol group (dSH) are good chelates such as DTPA
(diethylenetriamine pentaacetic acid) and gluceptate.
8. Oxidation state of technetium for labeling
Technetium is found in variable oxidation states ranging from 1 to +7, but it
frequently forms complexes in +5 oxidation state. A number of technetium com-
plexes with other oxidation states also exist in increasing order [10]. Complex of
technetium in +6, +2 and zero oxidation state are not synthesized because they are
not fruitful for medical purpose. Different complexes of technetium that they from
in different oxidation states are as follows:
• Complex of technetium in +7 oxidation state (Tc+7). Technetium naturally
occurs in this state, and it is most stable and nonreactive toward any chelating
agent in this oxidation state. Technetium in +7 oxidation state is found in the
form of technetium heptasulfide and pertechnetate 99mTcO4.
• Complex of technetium in +5 oxidation state (Tc+5). Technetium is present in
this oxidation state in the form of complexes such as99mTc-gluconate, 99mTc-
glucepetate, and 99mTc-citrate. During these complexes formation, reduction
of technetium (pertechnetate 99mTcO4) from +7 oxidation state to lower
oxidation state +5 is accomplished with stannous chloride in an aqueous
medium. It is observed that technetium in +5 oxidation state have tendency to
form the complex with sulfur containing molecules (dithiols) in solid state. In
these sulfur complexes, four sulfur atoms are located at the corner of the
square planes and oxygen atom at the apex of square pyramid. Compounds
with six coordination number are preferably formed in the aqueous medium,
and molecules exhibit more stable structure in the form of octahedral
geometry. Diaminodithiol (DATA) is one of the best examples of such
compounds. In these complexes, oxidation state of technetium is +5 and
complexes are neutral and stable in this oxidation state.
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• Complex of technetium in +4 oxidation state (Tc+4). Oxidation state of
technetium in complexes of TcO2 and hexahalo is +4. The reducing agent
which is used to reduce the pertechnetate 99mTcO4 from +7 oxidation state to
lower oxidation state +4 (TcO2.xH2O) is zinc with HCl. However, 20% of
technetium reduces to technetium metal by this method. In technetium-99m-
hydroxyethylidene diphosphonate (HEDP) complex, it is observed that the
oxidation state of technetium is changeable which is highly dependent upon
the pH of the method which is used to synthesize the complex. In acidic
medium, the oxidation state of technetium is +3; in alkaline medium, it is +5;
and in neutral medium, it is +4 [11]. This means that a slight change in pH can
change the oxidation state of technetium pointing to the fact that they may
exist as a mixture of all oxidation states like +3, +5 and +4 in technetium-99m-
hydroxyethylidene diphosphonate (HEDP) complex.
• Complex of technetium in +3 oxidation state (Tc+3). A number of technetium-
99m complexes exist with +3 oxidation state in acidic medium. These
complexes include DTPA (diethylenetriamine pentaacetic acid,
ethylenediamine tetraacetic acid (EDTA), DMSA (dimercaptosuccinic acid)
and hepatobiliary iminodiacetic acid. However, the oxidation state of
technetium in the complex EDTA and DTPA become +4 in alkaline as well as in
neutral medium. A variety of technetium complexes in which technetium
exists in +3 oxidation state are used for myocardial scanning. These include
complexes of technetium-99m with phosphine, arsine and BATOs (boronic
acid adduct of technetium dioxime comples).
• Complex of technetium in +1 oxidation state (Tc+1). This oxidation state is
stabilized with the help of coordinate covalent bond with different types of
ligands in aqueous medium. In this oxidation state, compounds are usually
stable in water and air.
9. Chemistry of indium and oxidation state for labeling
Indium belongs to aluminum which are naturally occurring transition metals. Its
chemical and physical properties are enlisted inTable 5. Indium is a soft silvery white
metal which is not found in free elemental form but found in the form of combined
state such as halides InCl3, InBr3 InI3 and InF3, sulphide and oxide (In2O3). Indium
exists in three oxidation state +3, +2 and +1 but indium in +3 oxidation state it appears
more stable. Thirty-nine isotopes of indium have been reported but only three
Properties of indium Values
Atomic number 49
Atomic mass (amu) 114.818
Electronic configuration 1s2,2s2,2p6,3s2,3p6,3d10,4s2,4p6,4d10,5s2,5p1
Density gm/cm3 (at 25°C) 7.31
Oxidation state +1,+2,+3, (+3 more stable)
Melting point in Kelvin 429.75
Boiling point in Kelvin 2353.15
Occurrence Solid state (naturally)
Electronegativity 1.78
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isotopes such as indium-111, indium-113 and indium-115 are commonly found.
Indium-111 with half-life of 66.32 hours are used in radiopharmaceutical for imaging
purpose [12]. γ-radiation emitted by indium-111 have an energy of 247 keV and
172 keV and the percentage of γ-radiation emitted by indium-111 is 90.6% with
minimal β-radiation emission that make the indium 111 a good imaging radiotracer.
Properties of indium Values
First, second and third ionization energy
(kJ/mol)
558, 1820, 2704, respectively
Electron affinity (kJ/mol) 29
Heat of vaporization kJ/mol 23.2
Group IIIA (13)
Metal category Poor metal (posttransitional)
Period 5th
Color Silvery white
Natural isotopes (two) Indium-113 and Indium-115
Artificial isotope 39 in number but Indium-111 and Indium-113 are
important
Table 5.
Physical and chemical properties of indium.
Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy
Refs.
1. Oxyquinolone-
labeled
leukocytes
111In Human
model
90% [1]
2. Exametazime-
labeled
leukocytes
99mTc Human
model
Reticuloendothelialsystem
visualization
90% [1]
Sulfur colloid 99mTc Human
model
osteomyelitis
3. Methylene
diphosphonate
99mTc Human
model
High
sensitivity low
specificity
[2]
4. Labeled
leukocytes
111In Human
model
[2]
5. HMPAO labeled
leukocytes
99mTc Human
model
[2]
6. Biotin 111In Human
model
Spinal infection 93% [2]
7. UBI 99mTc Human
model
Soft tissue and bone
infection
95% [3]
8. MDP 99mTc Human
model
Marrow imaging [4]
9. HMPAO-labeled
leukocyte
99mTc Human
model
Prosthetic joint infections 91% [5]
Table 6.
General radiopharmaceuticals developed based on SPECT imaging.
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These γ-emitting radionuclide labeled compounds can be utilized to identify the
exact position and location of the infection in different parts and organs such as
brain, arteries, joints, bones and tissues. In Table 6, a number of compounds bound
with γ-emitting radionuclides (indium-111 and technetium-99m) along with their
sensitivity and imaging purpose are shown.
10. Methods of radiolabeling
The radiolabeling of antibiotics, drugs, peptides, proteins and organic species
with different radiotracer has increased reasonably from imaging point of view in
medical, biochemical and other associated fields. In the field of medical imaging,
compounds are labeled with two types of radionuclides: (a) compound labeled with
those radionuclide that emitted the gamma radiation and have large number of
application and especially used for in vivo imaging of a number of organs and (b)
secondly, the compounds are labeled with radionuclide that emitted the β-radiation
and have limited in vitro study and therapeutic treatment of the disease site. During
the labeling process of a compound with a radiotracer, atoms or group of atoms of
compound are replaced by different or similar atoms or group of atoms of the
radiotracers [13]. In order to obtain, certain type of the labeling, the labeling
process is carried out under constant conditions of temperature, pressure and incu-
bation time. There are mainly six methods for labeling of the compound with
radiotracer as shown in Table 7.
11. Direct method labeling without bi-functional chelating agent
In this type of labeling process, there is no need of bi-functional chelating agents
or metal cheater. These are discussed below.
11.1 Isotopes exchange labeling
In this method, some atoms from the compound which is to be labeled is
replaced by isotope of the same atom of the element having different atomic mass
Isotopic exchange Labeling of the compounds with C-14, S-35, I-135 labeling of T3
and T4 and H-3.
Labeling with bifunctional
Chelating Agent
In-111 DTPA albumin
Tc-99m DTPA antibody
Introduction of foreign label Labellng of the proteins with I-125.
Tc-99m labeled radiopharmaceuticals
Labeling of the hormones with I-125
Labeling of the cells with In-111
F-18 fluorodeoxyglucose
Biosynthesis Labeling of the compounds with C-14
Co-57 cyanocobalamin
Se-75 selenomethionine
Excitation labeling Labeling of the compounds with I-223 from Xe-123 decay
Labeling of the compounds with Br-77 from Kr-77 decay
Recoil labeling Iodinated compounds
Compounds label with H-3
Table 7.
Methods for labeling of the compound with radiotracers [13].
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(more or less) such as I-123, I-124, I-125, I-127, and I-131. the compound is labeled
with isotope of the same element so the compound to be labeled and radiolabeled
are similar in biological properties, except for the energy emitted from different
isotopes of the same element which is used for labeling [14]. This method used for
in vitro study. Examples of isotope exchange labeling reactions are labeling of the
triiodothyronine (T3) with I-125, labeling of thyroxine with I-125, and labeling with
C-14, S-35 and H-3 labeled compounds [15].
11.2 Introduction of a foreign label
In this process of labeling, a molecule of known biological function is labeled
with a radionuclide. This labeling occurs by forming covalent bond or co-ordinate
covalent bond. The attaché radiotracer is unknown (foreign) to the molecule, and
labeling does not occur due to the exchange of its isotope. In most of these types of
compounds, chelation is the cause for bond formation. In such bonds, more than
one atom donates a pair of electrons to the foreign acceptor atom that is mostly a
transition metal. Majority of Tc-99m labeled compounds are developed by this
process such as binding of Tc-99m with DTPA, gluceptate, etc.
11.3 Biosynthesis
The biosynthesismethod involves the growth of themicroorganisms in a culture
medium that contains the radiotracer.Whenmicroorganisms (bacteria) grow in such a
medium, the radiotracer is introduced into themetabolites that are produced by the
metabolic activity of the organism. Thismetabolite is then chemically separated. Exam-
ple of such product is preparation of 57Co-B12 by using a bacterium Streptomyces griseus.
11.4 Recoil labeling
It is of limiting interest and cannot be preceded on large scale for labeling
because it has low specific activity of the bounded molecule. The method involves
generation of recoil ions or atoms as particles are emitted by the nucleus. These
generated atoms or ions then form a bond with the targeted molecule. This high
energy of recoil atoms gives poor yield.
11.5 Excitation labeling
Radioactive and very reactive daughter ions that are produced by nuclear decay
process are used in excitation labeling process. In β-decay and electron capture
processes, there is a production of highly energetic charged particle ions which have
the ability to label the compound of interest. When Kr-77 undergoes the decay
process, it yields Br-77. These (Br-77) energetic ions are able to bind the compound
of interest when exposed to it [16]. A number of proteins are labeled with I-123
when protein is exposed to Xe-123 which decays into energetic I-123 and label the
protein. Main disadvantage of this method is poor yield.
12. Indirect method labeling using bi-functional chelating agent
A chelating agent is a substance that has the ability to form multiple bonds with
a single metal ion, thus acts as a multidendate ligand. Bi-functional chelating agent
is that which has two are more separate covalent or coordinate covalent bonds with
a ligand which is polydendate in nature. The labeling process using bi-functional
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chelating agent involves the bond formation at two sites: one bond is formed by the
bi-functional chelating agent with macromolecule such as protein and antibody and
other bond is formed with metal ion such as Tc-99m. There are many bi-functional
chelating agents being used currently; however, most important are diethylene-
triamine pentaacetic acid (DTPA), metallothionein, diamide dimercaptide (N2S2),
dithiosemicarbazone, and hydrazinonicotinamide.
There are two types of labeling process by using bi-functional chelating agent.
(a) Tc-99m chelate method: In this method, a chemical is used to carry out
chelation (such as diamidodithiol and cyclam) and labeling of macromolecules such as
protein by forming the bond between chelating agent and protein (macromolecule).
(b) Indirect chelater antibody method: In this method, bi-functional chelating
agent forms a bond with macromolecule and then it reacts with metal ion to form
the complex known as metal-chelator-macromolecule complex. By using indirect
chelator antibody method, a number of antibodies are labeled. The biological func-
tion of the antibodies may be affected due to the presence of the chelating agent;
therefore, it is necessary to check the labeling products before a clinical trial. It is no
doubt that the prelabeled chelating method gives pure metal-chelate- complex with
precise structural study. However, the main drawback of this method is that it is a
lengthy procedure and gives poor yield [17].
These SPECT-radiopharmaceuticals can also be developed for early and accurate
diagnosis of cancer in different body parts and organs. A variety of drugs and
compounds such as peptides, proteins, antibodies, and organic species were labeled
with radionuclides such as indium-111 and technetium-99m, and these radiolabeled
compounds are used for the successful and accurate diagnosis of different types of
Sr.
no.
Labeled compound Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy
Refs.
1. Anti-PSMA
nanobody
111In Human
model
Tumor target [6]
2. HYNIC-Glu-Urea 99mTc Human
model
Metastatic prostate
cancer
[6]
5. DTPA-AMB8LK 111In Mice model Pancreatic cancer 23.6  3.9%
ID/g
[7]
6. Octreotide 111In Human
model
Neuroendocrine
tumor (NETs)
95% [8]
7. Sestamibi 99mTc Human
model
Parathyroid adenoma Range from
85 to 95%
[8]
8. MDP 99mTc Human
model
Bone metastases Very
sensitive
[8]
9. (Arg11)CCMSH 99mTc Mice model Murine melanoma 3.33  0.50%
ID/g
[9]
10. DOTA-Re(Arg11)
CCMSH
111In Mice model Murine melanoma 8.19  1.63%
ID/g
[9]
11. DTPA-octreotide 111In Mice model Lung cancer Bm/B was
3.1  0.6
[19]
12. HYNIC-TOC 99mTc Human
model
Metastatic
neuroendocrine
tumors
Sensitivity
87%
[10]
13. DTPA-octreotide 111In Mice model Somatostatin-
receptor tumors:
evaluation
4.3%ID/g [11]
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cancer in human and mice models [18]. In Table 8, a number of compounds which
are labeled with γ-emitting radiotracer for SPECT imaging of different types of
cancer with accuracy are shown.
SPECT-radiopharmaceuticals are not only used to identify infections and malig-
nancies but are equally used to know the effectiveness of the treatment strategy
which is used to cure the infections and tumors. That means, we can employ the
SPECT-radiopharmaceuticals for follow-up strategy to know about the effective-
ness of a treatment methods. A large numbers of radiolabeled compounds are being
used to identify the effects of previous treatment strategy, for example,
pentetreotide is labeled with indium-111 to follow-up of the neuroendocrine tumor
therapy (tumor generated due to the hormonal cell and nerves system) in gastroin-
testinal tract, lungs, pancreas, and rest of the body (Table 9).
Sr.
no.
Labeled compound Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy
Refs.
14. HYNIC-TOC 99mTc Mice model Somatostatin-
receptor tumors:
evaluation
5.8  9.6%
ID/g
[11]
15. HMPAO 99mTc Mice model Neuroblastoma 88% [12]
16. Oxine 111In Mice model Neuroblastoma 80% [12]
17. Rhenium sulfide
colloidal
nanoparticles
99mTc Rabbit
model
Sentinel lymph node Radiolabeled
98.5  0.5%
[13]
18. TDMPP complex 111In Mice model Tumor imaging [14]
19. DOTA conjugate -
TA138
111In Mouse
model
Tumor imaging 9.39% ID/g [15]
Table 8.
SPECT-radiopharmaceuticals using Tc-99m and In-111 for cancer imaging.
Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy
Refs.
1 Nano-colloids 99mTc Human
model
Breast cancer and
melanomas
Well accepted [16]
2 Radio-colloid 99mTc Human
model
Breast cancer, head/neck
malignancies, prostate
cancer and gynecological
malignancies
[16]
3 Pentetreotide 111In Human
model
Neuroendocrine tumors 95% [16]
4 Capromab 111In Human
model
Biochemical disease-free
survival and disease-
specific survival in primary
prostate cancer
46% [16]
5 Medronate 99mTc Human
model
Bone imaging [16]
6 Labeled white
blood cells
111In Human
model
Inflammation imaging [16]
7 Labeled white
blood
Cells
99mTc Human
model
Inflammation imaging [16]
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Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy
Refs.
8 Maraciclatide 99mTc Human
model
Angiogenesis [16]
9 3P-RGD2 99mTc [16]
10 MSAP-RGD 111In [1]
11 His-annexin
A5
C2AcH-
99mTc(CO)3 Apoptosis [2]
12 (Me)
FGCDEVD
99mTc [16]
13 DTPA-Ac-
TZ14011
111In Chemokine receptor 3
expression
[1]
14 AMD3100 99mTc [1]
15 DTPA-Fab-
PEG24-EGF
111In Epidermal growth factor
receptor
[1]
16 Etarfolatide 99mTc Folate receptor [1]
17 DOTA-folate 111In [1]
18 MIP1404 99mTc Prostate-specific
membrane
antigen
[1]
19 DPA-
alendronate
99mTc(CO)3 Bone imaging [1]
20 human
umbilical
tissue-derived
cells
111In Mice
model
Cerebral ischemia [17]
21 99mTc-pHLIP Mice
model
Lewis lung carcinoma
(LLC), lymph node
carcinoma of the prostate
(LNCaP) and prostate
adenocarcinoma
adequate
imageability and
correlation with
tumor
extracellular
acidity
[18]
22 99mTc-HHK Rat
model
Tumor microenvironment High specificity [18]
23 nanobody (Nb
cl1) against
CD206
radiolabeled
99mTc Mice
model
Macrophages in tumor [18]
24 99mTc-PyDA Mice
model
In vivo hypoxia targeting Selective uptake [18]
25 99mTc-
meropenem
Tumor hypoxia tissue [18]
26 99mTc-
nitroimidazole
Mice Differentiate from
inflamed and infected
tissues
[18]
27 99mTc-SD32 Breast tumor
cells
[18]
Table 9.
SPECT-radiopharmaceuticals using Tc-99m and In-111 for follow-up imaging.
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Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy/
efficiency
Refs.
1. HMPAO 99mTc Human
model
Painful prosthetic hip 39% (SD 12%) [20]
2. Tropolonate 111In Human
model
Painful prosthetic hip 63% (SD 14%) [20]
3. EDDA/HYNIC-
TOC
99mTc Human
model
Cancer diagnosis High tumor to
organ ratio
[21]
4. P829 peptide 99mTc Human
model
Neuroendocrine tumors 91% [22]
5. Pentetreotide 111In Human
model
Neuroendocrine tumors 65% [22]
6. labeled
leukocyte
111In Human
model
Osteomyelitis 91% [23]
7. HYNIC-TOC 99mTc Human
model
Metastatic
neuroendocrine tumors
Sensitivity 87% [10]
8. HYNIC-OC 99mTc Human
model
Tumor 0.70  0.13%ID/g [24]
9. HYNIC-TOC 99mTc Human
model
Malignancies 3.85  1.0 [24]
10. HYNIC-TATE 99mTc Human
model
Tumor 3.99  0.58%ID/g [24]
11. DTPA-OC 111In Human
model
Tumor 0.99  0.08%ID/g [24]
12. DOTA-TATE 111In Human
model
Tumor 4.12  0.74%ID/g [24]
13. Depreotide 99mTc Human
model
Lung cancer Immuno-
histochemical
correlations 98%
[25–
28]
14. DTPA 99mTc Human
model
Graves’ disease Specificity 89% [29]
15. HDP 99mTc Human
model
Bone imaging [30]
16. Tetrofosmin 99mTc Human
model
Glioblastoma
multiforme
L/N ratio of 4.7 [31]
17. ECD 99mTc Human
model
Alzheimer’s patients [32]
18. MAA 99mTc Human
model
Liver perfusion imaging 100% [33–
35]
19. Mebrofenin 99mTc Human
model
Hepatobiliary
Scintigraphy
[36]
20. HSA-DTPA 99mTc Human
model
Gastrointestinal
bleeding
70% [34]
21. GHA 99mTc Human
model
Brain-scanning 85% [37]
22. MDP 99mTc Human
model
Cerebral infarction [38]
23. DMSA 99mTc Human
model
Acute pyelonephritis [39]
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Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy/
efficiency
Refs.
24. Pyrophosphate 99mTc Human
model
Amyloidoses 97% [40]
25. Sulfur
Nanocolloid
99mTc Human
model
Lymphatic drainage
from prostate
3.9–5.2 mSv/MBq [41]
26. Oxine-labeled
leukocytes
111In Human
model
Liver cysts 87.5%
27. HMPAO-labeled
leukocyte
Tc-99m Human
model
Abscess [42]
28. MAA-and HAS
Microspheres
99mTc Human
model
Liver-lung shunt [35]
29. HSA-DTPA 99mTc Human
model
Gastrointestinal
bleeding
100% [34]
30. Labeled bone
marrow
mesenchymal
stem cells
111In Human
model
Acute brain trauma
model
[43]
31. Oxine 111In Human
model
Diagnostic imaging 80% [42]
32. HMPAO 99mTc Human
model
Diagnostic imaging 88% [42]
33. Sulfur
Nanocolloid
99mTc Human
model
Mapping of lymphatic
drainage from the
prostate
[41]
34. HMPAO-labeled
leukocyte
99mTc Human
model
Prosthetic joint
infections
91% [5]
35. Labeled
chimeric
monoclonal
antibody Nd2
111In Human
model
Pancreatic cancer 100% [44]
36. Labeled GnRH-I
tracer
111In Human
model
Tumor imaging Efficiency
11.8  1.9%
[45]
37. Oxine labeled
mesenchymal
stem cells
111In Human
model
Cirrhosis [46]
38. TRODAT-1 99mTc Human
model
Parkinson disease Target the pre-
synaptic dopamine
transporter (DAT)
[47]
39. Depreotide 99mTc Human
model
Lung cancer and other
pulmonary malignancies
96.6% [4]
40. Prostascint 99mTc Human
model
Prostate cancer Approved [4]
41. Zevalin 111In Human
model
Diagnosis of non-
Hodgkin’s lymphoma
Approved for use [4]
42. CEA scan 99mTc Human
model
Colon cancer Approved [4]
Octreo Scan 111In Human
model
Neuroendocrine tumors [4]
43. Depreotide 99mTc Human
model
Lung cancer [4]
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A number of SPECT-radiopharmaceuticals are being used in clinical trials which
are producing very fruitful results for the diagnosis of different types of cancers and
infections in human beings (Table 10). These radiolabeled compounds help doctors
obtain useful and precise information at a very early stage of the disease to identify
the extent of problem and to take timely decisions about the treatment strategies.
Future prospect
There is a need to develop more accurate, sensitive, precise, and reliable SPECT-
radiopharmaceuticals to identify the malignant infections and tumors at an early
stage in order to overcome the infectious diseases and cancer all over the world. If
cancer is diagnosed at an early stage, it would be easier to plan the exact treatment
strategy ahead of time. Considerable advancements have been made during last
decades in SPECT-radiopharmaceuticals that may take the place of instrumental
imaging techniques and therapeutic strategies. In combination with existing tech-
nologies, NMT may help a lot in the diagnostic and therapeutic advancement of
clinical detection methods.
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Sr
no.
Labeled
compound
Labeled
radioisotope
SPECT
imaging
model
Pathology Sensitivity/
accuracy/
efficiency
Refs.
44. Annexin-V 99mTc Human
model
Acute myocardial
infarction and
chemotherapy response
monitoring
[4]
45. Neuroligands 99mTc Human
model
Neuropsychiatric
patients
[4]
46. EC-MN 99mTc Human
model
Hypoxia [4]
Table 10.
Clinical trials study of different SPECT radiopharmaceuticals.
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